Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and - Takeaways - MDSpire

Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and

  • By

  • Shota Inoue

  • Ichiro Tsuboi

  • Marcin Miszczyk

  • Keiichiro Miyajima

  • Navid Roessler

  • Ahmed R. Alfarhan

  • Satoshi Katayama

  • Pierre I. Karakiewicz

  • Motoo Araki

  • Shahrokh F. Shariat

  • May 5, 2026

  • 0 min

Share

  • 1

    Immune checkpoint inhibitors (ICIs) enhance antitumor T-cell activity by blocking inhibitory pathways like PD-1 and CTLA-4.

  • 2

    Circadian rhythms influence immune cell function and checkpoint molecule expression, potentially affecting tumor immune evasion.

  • 3

    Chronotherapy aims to improve immunotherapy outcomes by timing drug administration to align with circadian rhythms.

  • 4

    This systematic review analyzed 29 studies to evaluate the impact of ICI administration timing on survival outcomes in advanced cancer.

  • 5

    The review included various cancer types and highlighted the need for further research on the clinical utility of chronomodulated immunotherapy.

Original Source(s)

Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and

  • by Shota Inoue, Ichiro Tsuboi, Marcin Miszczyk, Keiichiro Miyajima, Navid Roessler, Ahmed R. Alfarhan, Satoshi Katayama, Pierre I. Karakiewicz, Motoo Araki, Shahrokh F. Shariat

  • May 5, 2026

Related Content

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026